Congenital neutropenia: G-CSF vs stem cell transplant

The clinical consequence is a high risk of recurrent, severe bacterial infection. The estimated frequency is approximately 1–2 cases per million.

The treatment decision is not a simple comparison between medication and transplantation. G-CSF controls neutrophil production and prevents infectious complications in most children. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment, but it carries procedure-related risk and is not required immediately for every patient. The decision depends on ANC response, G-CSF dose, bone marrow findings, somatic mutations, cytogenetic evolution, and evidence of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

In practical terms, how to check G-CSF vs stem cell transplant requires longitudinal assessment. A single ANC value is insufficient.

The role of G-CSF in maintaining neutrophil homeostasis

G-CSF, including filgrastim, is the standard first-line therapy for children with SCN. It stimulates granulopoiesis and increases the circulating neutrophil count. Approximately 90% of patients achieve a clinically useful response, although the magnitude and durability of that response vary by genotype and disease biology.

The treatment objective is not normalization of every hematological parameter. The relevant endpoint is a sustained ANC that reduces severe bacterial infections while avoiding unnecessary dose escalation. Infection frequency, mucosal disease, fever episodes, hospitalization, and antibiotic requirements remain clinically relevant outcome measures. ANC is the principal biomarker, but it is not the only one.

A response to G-CSF generally has several components:

• A reproducible increase in ANC after treatment initiation or dose adjustment.
• Reduction in serious or recurrent bacterial infections.
• A stable dose requirement over time.
• Absence of progressive marrow dysplasia or malignant transformation.
• No emergence of high-risk molecular or cytogenetic abnormalities.

The pharmacodynamic response should be interpreted over repeated measurements. Neutrophil counts fluctuate with infection, recent antibiotic exposure, timing of the injection, and intercurrent inflammation. A measurement collected immediately after an acute infection does not establish baseline treatment efficacy. Serial ANC results are more informative than isolated peaks.

G-CSF is therefore a control strategy, not a curative intervention. It compensates for defective granulocyte production but does not correct the underlying pathogenic variant. In SCN associated with ELANE variants or other congenital defects of neutrophil development, the genetic mechanism remains active during therapy.

G-CSF can restore the biomarker that matters most for immediate infection control. It does not remove the molecular cause of congenital neutropenia.

The therapeutic response must also be separated from superficial dose-response behavior. A child may show a transient ANC increase at a high dose while remaining biologically unstable. Conversely, a patient with a lower ANC but a stable clinical course may not require immediate HSCT. Clinical utility is determined by the complete response profile, not by one laboratory target.

Identifying G-CSF refractoriness and dose escalation thresholds

Approximately 10% of children with SCN are refractory to G-CSF or fail to achieve adequate control at a clinically acceptable dose. Refractoriness should not be assigned after an inadequate trial caused by poor adherence, incorrect administration, underdosing, or insufficient observation time.

The assessment normally integrates four domains:

1. ANC response. Persistent severe neutropenia despite appropriate G-CSF exposure indicates inadequate pharmacodynamic response.

2. Infection control. Recurrent invasive or severe bacterial infections despite treatment suggest insufficient clinical protection.

3. Dose requirement. Escalating doses needed to maintain a safe ANC indicate declining treatment efficiency.

4. Disease evolution. New CSF3R mutations, increasing marrow blasts, dysplasia, or cytogenetic abnormalities shift the risk-benefit calculation toward HSCT.

There is no universal consensus that a single G-CSF dose automatically mandates transplantation in every asymptomatic child. The commonly used evaluation range is greater than approximately 8 to 20 µg/kg/day, but the exact threshold depends on the clinical context, genotype, marrow status, and transplant risk. This range should trigger formal transplant evaluation rather than function as an isolated compulsory indication.

A high dose has two distinct meanings. First, it may indicate that G-CSF is losing efficiency. Second, it may identify a disease course associated with clonal evolution. These are related but not identical observations. Dose escalation without molecular or marrow abnormalities does not prove malignant transformation. It does, however, reduce the margin for conservative management.

The table describes decision domains, not a validated scoring system. No single row replaces multidisciplinary review by pediatric hematology, immunology, transplant medicine, pathology, and molecular diagnostics.

The practical route for how to check G-CSF vs stem cell transplant in pediatric immunology is therefore sequential:

• Confirm the SCN phenotype with repeated ANC measurements and appropriate bone marrow assessment.
• Characterize the inherited cause where possible, including ELANE and other genes associated with inborn errors of immunity and congenital neutropenia.
• Establish the lowest G-CSF dose that provides stable clinical control.
• Monitor dose changes, infection burden, marrow morphology, cytogenetics, and somatic mutation status.
• Repeat risk assessment when the dose rises, the ANC becomes unstable, or new hematologic abnormalities appear.
• Refer for HSCT planning before transformation when the risk profile becomes unfavorable.

This process prevents two opposite errors. Immediate transplantation can expose a clinically controlled child to avoidable transplant toxicity. Indefinite reliance on G-CSF can delay definitive treatment after the disease has acquired high-risk features.

Genetic markers and the risk of leukemic transformation

Genetic diagnostics are central to SCN management because the inherited pathogenic variant defines the biological substrate, while acquired mutations provide evidence of clonal evolution.

ELANE is a major disease-associated gene in congenital neutropenia. Long-term G-CSF-treated patients with ELANE-mutated SCN have been reported to carry a cumulative risk of MDS or AML of up to 15–25% over time. This figure should not be interpreted as proof that G-CSF independently causes leukemia. The risk reflects the underlying genetic instability of SCN and the acquisition of somatic abnormalities during disease evolution.

The most clinically relevant acquired marker in this context is a somatic activating mutation in CSF3R, the gene encoding the G-CSF receptor. CSF3R mutations may emerge under the selective pressure of chronic granulopoietic stimulation and are associated with clonal progression. Their presence does not, by itself, establish AML. It identifies a higher-risk molecular state that requires integration with marrow morphology, blast count, cytogenetics, and additional mutations.

Molecular surveillance should not be reduced to a binary result. A negative assay does not eliminate risk. It means that the tested specimen and assay design did not detect the targeted alteration above the assay’s limit of detection. Results depend on:

• The sequencing platform and its analytical sensitivity.
• Variant allele frequency in the tested specimen.
• Peripheral blood versus bone marrow sampling.
• Coverage of CSF3R and other relevant genes.
• Detection of small subclones.
• Confirmation of variants with orthogonal methods when clinically necessary.

A targeted panel may provide high analytical specificity for known genes and a controlled reporting workflow. Its limitation is scope. A panel cannot detect pathogenic variants outside its content, structural changes it was not designed to identify, or newly relevant genes absent from the assay.

Whole-exome sequencing (WES) provides broader coding-region coverage and may be useful when the phenotype is atypical, the initial panel is negative, or the clinical team suspects a rare genetic cause. Its limitations include incomplete coverage of some exons, weaker performance for certain structural variants, difficulty interpreting variants of uncertain significance, and less consistent sensitivity for low-level somatic clones. WES is not automatically superior for every clinical question.

The assay result must be linked to the clinical decision. Detecting a CSF3R mutation in a child with stable ANC, no dysplasia, and no blast excess is not equivalent to diagnosing leukemia. It is a surveillance and risk-stratification finding. Conversely, a negative somatic panel cannot neutralize progressive marrow dysplasia or rising blasts.

Bone marrow findings and the threshold for transplantation

Bone marrow examination remains a central component of longitudinal SCN monitoring. The baseline pattern typically includes maturation arrest in the promyelocyte or myelocyte stage. That finding supports the diagnosis but does not, by itself, determine whether G-CSF should be continued or HSCT should be performed.

The clinically decisive changes are acquired abnormalities:

• Increasing blast counts.
• New or progressive dysplasia.
• Cytogenetic evolution.
• Clonal molecular findings associated with MDS or AML.
• Failure of granulopoiesis despite increasing G-CSF exposure.

The distinction between a stable congenital maturation defect and an evolving myeloid neoplasm is operationally important. A stable marrow phenotype can be compatible with long-term G-CSF management. A changing phenotype requires a different clinical pathway, even if the ANC remains temporarily acceptable.

Bone marrow blast counts should be interpreted with morphology and molecular data. A single borderline result may require confirmation, particularly when specimen quality is limited or infection has altered hematopoiesis. Progressive abnormalities carry more weight than isolated, non-reproducible findings.

The transplant referral point should precede overt leukemia whenever the accumulated evidence indicates that the disease is becoming biologically unsafe to manage with G-CSF alone. This is the central distinction between pre-emptive HSCT and rescue transplantation after malignant transformation.

Timing the transition to allogeneic stem cell transplantation

Allogeneic HSCT replaces the patient’s defective hematopoietic system with donor-derived stem cells. For congenital neutropenia, it remains the only curative therapy. The intervention is therefore justified when the expected long-term risk of continued disease control becomes greater than the expected transplant risk.

The strongest indications include:

• Refractoriness to G-CSF.
• A requirement for escalating or unusually high G-CSF doses.
• Severe infections despite treatment.
• Acquired CSF3R mutations in a concerning clinical or marrow context.
• Progressive cytogenetic or molecular abnormalities.
• MDS or AML transformation.
• Inability to maintain a safe and clinically useful ANC.

The timing is more difficult in a child who responds to G-CSF at a stable dose and has no evidence of clonal evolution. In that setting, immediate HSCT is not automatically indicated. The transplant team must assess donor availability, conditioning strategy, organ status, infection history, genotype, and the child’s current marrow risk.

A transplant decision should be based on a trend rather than a snapshot. Relevant trends include:

• Rising G-CSF dose over successive assessments.
• Declining ANC response at a previously effective dose.
• Increasing infection burden.
• Emergence or expansion of somatic clones.
• Progressive marrow dysplasia.
• Increasing blast counts.
• New cytogenetic abnormalities.

The exact dose threshold remains context-dependent. The available evidence supports using the range above approximately 8–20 µg/kg/day as a trigger for detailed HSCT assessment, not as a universal mandate. Some children may require transplantation at a lower dose if they have high-risk molecular or marrow findings. Others may be observed under intensive surveillance when the dose is higher but the response is stable and no additional risk markers are present. The latter approach requires disciplined follow-up, not therapeutic inertia.

There is also no established long-term clinical-trial framework proving that newer targeted therapies outperform early elective HSCT in children who respond to low-dose G-CSF. This uncertainty limits algorithmic treatment. Clinical decisions remain based on response kinetics, genotype, clonal surveillance, marrow pathology, and transplant-specific risk.

For families and clinical teams, the decision pathway is easier to interpret when divided into three states:

Stable G-CSF-responsive SCN

The child maintains a clinically useful ANC, serious infections decrease, the dose remains stable, and marrow and molecular surveillance show no concerning evolution. G-CSF remains the management strategy. Monitoring continues because response does not equal cure.

G-CSF-dependent or biologically concerning SCN

The child requires escalating doses, has an unstable ANC, develops recurrent severe infection, or shows emerging somatic abnormalities. HSCT planning should begin or accelerate. This is the stage at which a transplant can potentially be performed before overt leukemia.

Transformed SCN

The child develops MDS or AML, significant blast excess, or definitive malignant evolution. HSCT becomes urgent and technically more complex. Outcomes are inferior to those achieved when transplantation is performed before leukemic transformation.

Survival outcomes: pre-emptive versus post-leukemic transplantation

Timing has a measurable clinical effect. Pediatric patients transplanted for SCN before leukemic transformation achieve significantly better post-transplant survival than those transplanted after developing MDS or AML.

The reason is not limited to the presence of leukemia. Transformation introduces a higher disease burden, more abnormal hematopoietic clones, greater conditioning complexity, and increased infection and organ complications. The patient may arrive at transplantation after prolonged neutropenia, repeated invasive infections, and prior intensive therapy. Each factor can reduce transplant tolerance.

This does not mean that all children with SCN should undergo early HSCT. It means that delaying transplantation until malignant transformation is an unfavorable strategy when high-risk markers have already accumulated. The clinical objective is risk discrimination: identify children for whom G-CSF remains an effective control therapy and separate them from children in whom the underlying clone is progressing.

The comparative outcome can be summarized as follows:

The table describes relative clinical positioning rather than fixed survival percentages. The supplied evidence supports the direction of the difference but does not establish one universal survival estimate applicable to every genotype, donor source, conditioning regimen, or transplant center.

Clinical utility of the comparison

G-CSF and HSCT answer different clinical problems.

G-CSF provides hematologic control. Its value is measured through ANC response, infection reduction, dose stability, and tolerability. It is suitable for children who maintain a reliable response without evidence of clonal progression. It does not eliminate the inherited defect or the long-term risk of malignant transformation.

HSCT provides definitive hematopoietic replacement. Its value is greatest when the disease has become refractory, when dose requirements are escalating, or when molecular and marrow surveillance indicate a high-risk trajectory. Its timing matters because transplantation before MDS or AML transformation produces better outcomes than rescue transplantation after leukemia develops.

A technically valid assessment of how to check G-CSF vs stem cell transplant therefore requires the following hierarchy:

1. Confirm the phenotype. Persistent ANC below 500 cells/µl and compatible marrow findings establish the severe congenital neutropenia framework.

2. Define the molecular substrate. Germline testing identifies the pathogenic variant and informs disease-specific surveillance.

3. Quantify treatment response. ANC, infection burden, and dose requirement must be tracked longitudinally.

4. Search for clonal evolution. CSF3R mutations, additional high-risk mutations, cytogenetic changes, dysplasia, and blast expansion alter the risk profile.

5. Evaluate transplant risk before transformation. A child with worsening biological markers should not wait for AML before transplant planning.

6. Use HSCT as the curative option. G-CSF remains supportive and disease-controlling, not curative.

The clinical utility is consequently conditional, not binary. G-CSF is appropriate when it provides durable control with acceptable dose exposure and no evidence of progression. HSCT is appropriate when medical control fails or when disease biology indicates that continued dependence on G-CSF is no longer sufficiently safe. The decisive variables are assay-supported molecular findings, marrow pathology, ANC kinetics, and treatment dose—not preference for one modality in isolation.